Xinxiang Tuoxin Pharmaceutical Co. LtdJune 6, 2019

FDA 483 - Xinxiang Tuoxin Pharmaceutical Co. Ltd - June 06, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Xinxiang Tuoxin Pharmaceutical Co. Ltd

Record Details

An FDA inspection of Xinxiang Tuoxin Pharmaceutical Co., Ltd in Xinxiang, China, revealed significant deficiencies across multiple areas of their operations. The firm failed to adequately establish impurity profiles, validate analytical methods, ensure data integrity in computerized systems, and properly handle product quality complaints. These observations indicate a need for improved quality control and adherence to good manufacturing practices.

Company: Xinxiang Tuoxin Pharmaceutical Co. Ltd
Inspection Date: June 6, 2019
Product Type: Drugs
Office: Office of Biological Products Operations - Division I
Person: Yasamin Ameri (Compliance Officer)

Open in Dashboard

ID · 8eff03f5-2bc3-4e9a-95ce-4be2647445c7